Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography
Launched by GE HEALTHCARE · Sep 1, 2015
Trial Information
Current as of May 29, 2025
Terminated
Keywords
ClinConnect Summary
ADAPT-ENRICH will supplement an on-going program (ADAPT) which consists of 2 additional recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to l...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged 30 years or older (≥30 years old);
- • Initially asymptomatic women who underwent routine bilateral screening with Digital Breast Tomosynthesis (DBT), followed by diagnostic work-up showing one or more abnormalities and referred for breast biopsy;
- • Are able and willing to comply with study procedures;
- • Have signed and dated the informed consent form;
- • Documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy.
- Exclusion Criteria:
- • Have been previously included in this study , ADAPT-SCR recruitment plan or ADAPT-BX recruitment plan;
- • Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including mastectomy and cytopunction, before study-related imaging;
- • Have breasts too large to be adequately positioned on 24 x 31 centimeter (cm) DBT or FFDM digital receptor without anatomical cut-off during a DBT or FFDM examination;
- • Have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes;
- • Have breast implant(s);
- • Have reconstructed breast(s).
About Ge Healthcare
GE Healthcare is a leading global medical technology and digital solutions innovator, dedicated to improving patient outcomes through advanced imaging, monitoring, and diagnostics. With a commitment to enhancing healthcare delivery, GE Healthcare develops cutting-edge technologies and clinical applications that empower healthcare professionals to make informed decisions. By leveraging extensive research and development capabilities, the organization actively sponsors clinical trials aimed at validating new therapies and medical devices, ensuring that they meet the highest standards of safety and efficacy. Through collaboration with healthcare providers and institutions, GE Healthcare strives to drive innovation and improve the efficiency of healthcare systems worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greenville, North Carolina, United States
Sioux Falls, South Dakota, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials